Skip to search formSkip to main contentSkip to account menu

ABT-530

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzimidazolesPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir
ABSTRACT The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and… 
Review
2016
Review
2016
Analysis of Hepatitis C Virus (HCV) Genotype 2 and 3 Variants in Patients Treated With Combination Therapy of Next-Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530
Background. ABT-493 (NS3/4A protease inhibitor identified by AbbVie and Enanta) and ABT-530 (NS5A inhibitor) are next-generation… 
2014
2014
Engagement in der Hepatitis-C-Forschung
Das klinische Entwicklungsprogramm von AbbVie zu HCV ist darauf ausgerichtet, durch die Erforschung eines interferonfreien, rein… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)